Moleculin Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The MIRACLE phase III trial for relapsed/refractory AML is progressing rapidly, with interim unblinded data for 45 patients expected soon. Annamycin shows strong efficacy, zero cardiotoxicity, and broad organ targeting, positioning it for significant market impact and multiple upcoming milestones.
-
Leadership highlighted deep experience and investment, with Annamycin positioned as a non-cardiotoxic, next-generation anthracycline. Phase 2 data showed strong remission rates in AML, and the adaptive Phase 3 MIRACLE trial offers near-term data visibility and significant market potential.
Fiscal Year 2025
-
MB-107 phase 1B/2 trial of Annamycin in advanced soft tissue sarcoma lung metastases showed a median overall survival of 13.5 months in a heavily pretreated population, with optimal dosing yielding nearly 20 months OS and a clinical benefit rate over 59%. No drug-related cardiotoxicity was observed.
-
Phase III MIRACLE trial for Annamycin in AML is underway globally, with EMA and FDA approvals advancing and first patient treated. Cash runway extends into Q3 2025, with $15M more needed for key milestones. Interim data readouts and final MD-107 results are expected soon.
Fiscal Year 2024
-
MIRACLE phase 3 trial for Annamycin in AML is underway with strong phase 2 results and multiple interim data readouts planned. Financially, $13M in cash extends runway into Q3 2025, with increased burn expected in 2026. Annamycin shows promise as a non-cardiotoxic anthracycline.
-
Annamycin's phase III MIRACLE trial for AML is advancing with strong phase II results, adaptive design, and global site engagement. Cash runway extends into Q1 2025, with key interim data expected by mid-2026 and a rolling NDA planned for 2028.
-
Annamycin, a non-cardiotoxic anthracycline, is showing a 50% CR rate in second-line AML, far surpassing current therapies. The pivotal Miracle trial, with robust design and FDA alignment, aims for key data readouts in 2025-2026, potentially transforming AML treatment.
-
Annamycin, a next-generation anthracycline, shows superior efficacy and no cardiotoxicity in AML, with pivotal phase 3 trials set to begin. Regulatory support, strong clinical data, and a robust financial position highlight significant market and patient impact.
-
Annamycin, a novel anthracycline, has shown promising efficacy and safety in relapsed/refractory AML, with a 50% complete remission rate and no observed cardiotoxicity. The adaptive phase III MIRACLE trial, starting in Q1 2025, aims to confirm these results and expedite regulatory approval.